Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.

[Visual acuity in anti-VEGF therapy for AMD : Can specific characteristics in the SD-OCT help?] Ophthalmologe (2017) 0.75

Visual and Morphologic Outcomes in Eyes with Hard Exudate in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmol Retina (2017) 0.75

Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology (2012) 2.19

Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.73

Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.57

Position of the fovea centralis with respect to the optic nerve head. Optom Vis Sci (1992) 1.13

Review of retinal angiomatous proliferation or type 3 neovascularization. Retina (2008) 1.10

Cystoid macular edema. Optom Clin (1996) 1.04

Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. Br J Ophthalmol (2014) 0.88

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 3.85

Intravitreal aflibercept for diabetic macular edema. Ophthalmology (2014) 3.49

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology (2013) 2.40

Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema. JAMA Ophthalmol (2014) 1.71

Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2014) 1.45

Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology (2015) 1.29

Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol (2014) 1.20

Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.07

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 1.04

Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. JAMA Ophthalmol (2016) 0.96

Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.94

Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology (2014) 0.89

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.88

Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2015) 0.86

Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2015) 0.85

Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2015) 0.84

Peripheral Retinal Changes Associated with Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 12 by the Age-Related Eye Disease Study 2 Optos PEripheral RetinA (OPERA) Study Research Group. Ophthalmology (2017) 0.84

Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2014) 0.83

Natural History of Geographic Atrophy Progression Secondary to Age-Related Macular Degeneration (Geographic Atrophy Progression Study). Ophthalmology (2015) 0.82

Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology (2015) 0.82

Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology (2015) 0.82

The Practice Impact of Electronic Health Record System Implementation Within a Large Multispecialty Ophthalmic Practice. JAMA Ophthalmol (2015) 0.82

Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology (2016) 0.78

Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol (2016) 0.76

Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2015) 0.76

Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema. JAMA Ophthalmol (2016) 0.76

Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology (2017) 0.75

Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.75

The Use of a Mobile Van for School Vision Screening: Results of 63 841 Evaluations. Am J Ophthalmol (2015) 0.75

Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents. JAMA Ophthalmol (2020) 0.75

Counterfeit Avastin in India: Punish the Criminals, Not the Patients. Am J Ophthalmol (2016) 0.75

Association of Pediatric Choroidal Neovascular Membranes at the Temporal Edge of Optic Nerve and Retinochoroidal Coloboma. Am J Ophthalmol (2016) 0.75

Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies. Ophthalmology (2017) 0.75